S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation

Windtree Therapeutics (WINT) Competitors

$0.39
+0.03 (+8.34%)
(As of 03/1/2024 ET)

WINT vs. ELOX, NSTGQ, SCNI, PKBO, TCBP, FNCH, KRBP, PALI, ALBT, and NSTG

Should you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Eloxx Pharmaceuticals (ELOX), NanoString Technologies (NSTGQ), Scinai Immunotherapeutics (SCNI), Peak Bio (PKBO), TC Biopharm (TCBP), Finch Therapeutics Group (FNCH), Kiromic BioPharma (KRBP), Palisade Bio (PALI), Avalon GloboCare (ALBT), and NanoString Technologies (NSTG). These companies are all part of the "biological products, except diagnostic" industry.

Windtree Therapeutics vs.

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability.

Windtree Therapeutics' return on equity of 0.00% beat Eloxx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Eloxx PharmaceuticalsN/A N/A -203.00%
Windtree Therapeutics N/A -274.89%-66.31%

Eloxx Pharmaceuticals currently has a consensus price target of $55.00, suggesting a potential upside of 6,083.25%. Given Windtree Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than Windtree Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eloxx Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Windtree Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Windtree Therapeutics had 3 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 3 mentions for Windtree Therapeutics and 0 mentions for Eloxx Pharmaceuticals. Eloxx Pharmaceuticals' average media sentiment score of 1.28 beat Windtree Therapeutics' score of 0.00 indicating that Windtree Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Eloxx Pharmaceuticals Neutral
Windtree Therapeutics Positive

8.6% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.0% of Windtree Therapeutics shares are owned by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 0.8% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Eloxx Pharmaceuticals received 10 more outperform votes than Windtree Therapeutics when rated by MarketBeat users. However, 50.00% of users gave Windtree Therapeutics an outperform vote while only 43.33% of users gave Eloxx Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Eloxx PharmaceuticalsOutperform Votes
13
43.33%
Underperform Votes
17
56.67%
Windtree TherapeuticsOutperform Votes
3
50.00%
Underperform Votes
3
50.00%

Eloxx Pharmaceuticals has a beta of 2.73, indicating that its share price is 173% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.

Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eloxx PharmaceuticalsN/AN/A-$36.06M-$9.07-0.10
Windtree TherapeuticsN/AN/A-$39.21M-$20.27-0.02

Summary

Eloxx Pharmaceuticals beats Windtree Therapeutics on 9 of the 15 factors compared between the two stocks.


Get Windtree Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WINT vs. The Competition

MetricWindtree TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$2.01M$2.77B$5.06B$7.63B
Dividend YieldN/A2.38%2.82%3.87%
P/E Ratio-0.0216.96179.7513.89
Price / SalesN/A267.863,041.2576.80
Price / CashN/A31.2298.6855.35
Price / Book0.034.474.524.54
Net Income-$39.21M-$6.05M$114.79M$211.55M
7 Day Performance22.63%5.88%5.67%3.36%
1 Month Performance-2.63%15.47%11.17%6.69%
1 Year Performance-93.56%12.78%14.01%8.88%

Windtree Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELOX
Eloxx Pharmaceuticals
1.2791 of 5 stars
$0.76
flat
$55.00
+7,127.3%
-73.1%$2.39MN/A-0.0818
NSTGQ
NanoString Technologies
0 of 5 stars
$0.05
-16.7%
N/AN/A$2.41M$127.26M-0.01550Gap Down
SCNI
Scinai Immunotherapeutics
0 of 5 stars
$0.50
+4.2%
N/AN/A$938,000.00N/A-0.1533Short Interest ↑
News Coverage
Gap Up
PKBO
Peak Bio
0 of 5 stars
$0.04
flat
N/A-99.8%$853,000.00$610,000.000.0021
TCBP
TC Biopharm
0.4115 of 5 stars
$1.16
+7.4%
$1,400.00
+120,589.7%
-99.8%$785,000.00$2.86M0.0060Short Interest ↑
FNCH
Finch Therapeutics Group
1.1055 of 5 stars
$2.42
-3.2%
$210.00
+8,577.7%
-77.4%$3.90M$860,000.00-0.0418Short Interest ↑
Gap Down
KRBP
Kiromic BioPharma
0 of 5 stars
$3.02
+2.7%
N/A-48.6%$3.90MN/A0.0031News Coverage
Gap Up
PALI
Palisade Bio
3.7166 of 5 stars
$0.44
+2.3%
$8.75
+1,888.6%
-81.2%$4.08MN/A0.0012Short Interest ↓
Gap Up
ALBT
Avalon GloboCare
0 of 5 stars
$0.39
+2.6%
N/A-81.4%$4.29M$1.23M0.005News Coverage
NSTG
NanoString Technologies
3.353 of 5 stars
N/A$7.63
+∞
N/A$5.07M$127.26M-0.03550Analyst Report
Gap Down

Related Companies and Tools

This page (NASDAQ:WINT) was last updated on 3/2/2024 by MarketBeat.com Staff